Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1975 2
1976 4
1977 4
1979 2
1980 1
1985 5
1986 5
1987 3
1988 1
1989 4
1990 11
1991 12
1992 10
1993 9
1994 9
1995 7
1996 12
1997 19
1998 20
1999 30
2000 25
2001 28
2002 43
2003 38
2004 49
2005 64
2006 78
2007 69
2008 85
2009 103
2010 106
2011 114
2012 161
2013 167
2014 206
2015 232
2016 152
2017 118
2018 187
2019 216
2020 223
2021 262
2022 270
2023 256
2024 28

Text availability

Article attribute

Article type

Publication date

Search Results

3,116 results

Results by year

Filters applied: . Clear all
Page 1
A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity.
Jacob F, Salinas RD, Zhang DY, Nguyen PTT, Schnoll JG, Wong SZH, Thokala R, Sheikh S, Saxena D, Prokop S, Liu DA, Qian X, Petrov D, Lucas T, Chen HI, Dorsey JF, Christian KM, Binder ZA, Nasrallah M, Brem S, O'Rourke DM, Ming GL, Song H. Jacob F, et al. Among authors: ming gl. Cell. 2020 Jan 9;180(1):188-204.e22. doi: 10.1016/j.cell.2019.11.036. Epub 2019 Dec 26. Cell. 2020. PMID: 31883794 Free PMC article.
We further demonstrate the utility of GBOs to test personalized therapies by correlating GBO mutational profiles with responses to specific drugs and by modeling chimeric antigen receptor T cell immunotherapy. Our studies show that GBOs maintain many key features of gliobl …
We further demonstrate the utility of GBOs to test personalized therapies by correlating GBO mutational profiles with responses to specific …
Rgs16 promotes antitumor CD8(+) T cell exhaustion.
Weisshaar N, Wu J, Ming Y, Madi A, Hotz-Wagenblatt A, Ma S, Mieg A, Hering M, Zettl F, Mohr K, Schlimbach T, Ten Bosch N, Hertel F, Müller L, Byren H, Wang M, Borgers H, Munz M, Schmitt L, van der Hoeven F, Kloz U, Carretero R, Schleußner N, Jackstadt RF, Hofmann I, Cui G. Weisshaar N, et al. Among authors: ming y. Sci Immunol. 2022 May 27;7(71):eabh1873. doi: 10.1126/sciimmunol.abh1873. Epub 2022 May 27. Sci Immunol. 2022. PMID: 35622904
T cells become functionally exhausted in tumors, limiting T cell-based immunotherapies. Although several transcription factors regulating the exhausted T (T(ex)) cell differentiation are known, comparatively little is known about the regulators of T …
T cells become functionally exhausted in tumors, limiting T cell-based immunotherapies. Although several transcription factors …
BTN3A1 governs antitumor responses by coordinating alphabeta and gammadelta T cells.
Payne KK, Mine JA, Biswas S, Chaurio RA, Perales-Puchalt A, Anadon CM, Costich TL, Harro CM, Walrath J, Ming Q, Tcyganov E, Buras AL, Rigolizzo KE, Mandal G, Lajoie J, Ophir M, Tchou J, Marchion D, Luca VC, Bobrowicz P, McLaughlin B, Eskiocak U, Schmidt M, Cubillos-Ruiz JR, Rodriguez PC, Gabrilovich DI, Conejo-Garcia JR. Payne KK, et al. Among authors: ming q. Science. 2020 Aug 21;369(6506):942-949. doi: 10.1126/science.aay2767. Science. 2020. PMID: 32820120 Free PMC article.
Gamma delta (gammadelta) T cells infiltrate most human tumors, but current immunotherapies fail to exploit their in situ major histocompatibility complex-independent tumoricidal potential. Activation of gammadelta T cells can be elicited by butyrophilin and butyroph …
Gamma delta (gammadelta) T cells infiltrate most human tumors, but current immunotherapies fail to exploit their in situ major histoc …
LAG3 ectodomain structure reveals functional interfaces for ligand and antibody recognition.
Ming Q, Celias DP, Wu C, Cole AR, Singh S, Mason C, Dong S, Tran TH, Amarasinghe GK, Ruffell B, Luca VC. Ming Q, et al. Nat Immunol. 2022 Jul;23(7):1031-1041. doi: 10.1038/s41590-022-01238-7. Epub 2022 Jun 27. Nat Immunol. 2022. PMID: 35761082 Free PMC article.
The immune checkpoint receptor lymphocyte activation gene 3 protein (LAG3) inhibits T cell function upon binding to major histocompatibility complex class II (MHC class II) or fibrinogen-like protein 1 (FGL1). ...These insights can guide LAG3-based drug development and imp …
The immune checkpoint receptor lymphocyte activation gene 3 protein (LAG3) inhibits T cell function upon binding to major histocompat …
The malate shuttle detoxifies ammonia in exhausted T cells by producing 2-ketoglutarate.
Weisshaar N, Ma S, Ming Y, Madi A, Mieg A, Hering M, Zettl F, Mohr K, Ten Bosch N, Stichling D, Buettner M, Poschet G, Klinke G, Schulz M, Kunze-Rohrbach N, Kerber C, Klein IM, Wu J, Wang X, Cui G. Weisshaar N, et al. Among authors: ming y. Nat Immunol. 2023 Nov;24(11):1921-1932. doi: 10.1038/s41590-023-01636-5. Epub 2023 Oct 9. Nat Immunol. 2023. PMID: 37813964 Free PMC article.
Got1 deficiency decreased the NAD(+)/NADH ratio and limited antiviral CD8(+) T cell responses to chronic infection; however, increasing the NAD(+)/NADH ratio did not restore T cell responses. ...These data indicate that the major function of the malate shuttle in CD …
Got1 deficiency decreased the NAD(+)/NADH ratio and limited antiviral CD8(+) T cell responses to chronic infection; however, increasi …
TBX6 null variants and a common hypomorphic allele in congenital scoliosis.
Wu N, Ming X, Xiao J, Wu Z, Chen X, Shinawi M, Shen Y, Yu G, Liu J, Xie H, Gucev ZS, Liu S, Yang N, Al-Kateb H, Chen J, Zhang J, Hauser N, Zhang T, Tasic V, Liu P, Su X, Pan X, Liu C, Wang L, Shen J, Shen J, Chen Y, Zhang T, Zhang J, Choy KW, Wang J, Wang Q, Li S, Zhou W, Guo J, Wang Y, Zhang C, Zhao H, An Y, Zhao Y, Wang J, Liu Z, Zuo Y, Tian Y, Weng X, Sutton VR, Wang H, Ming Y, Kulkarni S, Zhong TP, Giampietro PF, Dunwoodie SL, Cheung SW, Zhang X, Jin L, Lupski JR, Qiu G, Zhang F. Wu N, et al. Among authors: ming y, ming x. N Engl J Med. 2015 Jan 22;372(4):341-50. doi: 10.1056/NEJMoa1406829. Epub 2015 Jan 7. N Engl J Med. 2015. PMID: 25564734 Free PMC article.
Generation and biobanking of patient-derived glioblastoma organoids and their application in CAR T cell testing.
Jacob F, Ming GL, Song H. Jacob F, et al. Among authors: ming gl. Nat Protoc. 2020 Dec;15(12):4000-4033. doi: 10.1038/s41596-020-0402-9. Epub 2020 Nov 9. Nat Protoc. 2020. PMID: 33169003
In addition, we describe procedures for investigating patient-specific responses to immunotherapies by co-culturing GBOs with chimeric antigen receptor (CAR) T cells. It takes ~2-4 weeks to generate GBOs and 5-7 d to perform CAR T cell co-culture using this protocol …
In addition, we describe procedures for investigating patient-specific responses to immunotherapies by co-culturing GBOs with chimeric antig …
The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions.
Li Y, Ming Y, Fu R, Li C, Wu Y, Jiang T, Li Z, Ni R, Li L, Su H, Liu Y. Li Y, et al. Among authors: ming y. Front Pharmacol. 2022 Oct 14;13:950923. doi: 10.3389/fphar.2022.950923. eCollection 2022. Front Pharmacol. 2022. PMID: 36313336 Free PMC article. Review.
Although CAR-T therapy is an effective treatment for many malignancies, it also causes adverse effects. ...Severe adverse reactions complicated by CRS severely impede the widespread application of CAR-T therapy. The CAR-T product was initially approved in 201 …
Although CAR-T therapy is an effective treatment for many malignancies, it also causes adverse effects. ...Severe adverse reactions c …
Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis.
Hamilton JD, Suárez-Fariñas M, Dhingra N, Cardinale I, Li X, Kostic A, Ming JE, Radin AR, Krueger JG, Graham N, Yancopoulos GD, Pirozzi G, Guttman-Yassky E. Hamilton JD, et al. Among authors: ming je. J Allergy Clin Immunol. 2014 Dec;134(6):1293-1300. doi: 10.1016/j.jaci.2014.10.013. J Allergy Clin Immunol. 2014. PMID: 25482871 Free article. Clinical Trial.

Significant (P < .05) decreases in mRNA expression of genes related to hyperplasia (K16 and MKI67), T cells, and dendritic cells (CD1b and CD1c) and potent inhibition of TH2-associated chemokines (CCL17, CCL18, CCL22, and CCL26) were noted without significant modulation

…

Significant (P < .05) decreases in mRNA expression of genes related to hyperplasia (K16 and MKI67), T cells, and dendritic cells (

…
Fucosylation of HLA-DRB1 regulates CD4(+) T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy.
Lester DK, Burton C, Gardner A, Innamarato P, Kodumudi K, Liu Q, Adhikari E, Ming Q, Williamson DB, Frederick DT, Sharova T, White MG, Markowitz J, Cao B, Nguyen J, Johnson J, Beatty M, Mockabee-Macias A, Mercurio M, Watson G, Chen PL, McCarthy S, MoranSegura C, Messina J, Thomas KL, Darville L, Izumi V, Koomen JM, Pilon-Thomas SA, Ruffell B, Luca VC, Haltiwanger RS, Wang X, Wargo JA, Boland GM, Lau EK. Lester DK, et al. Among authors: ming q. Nat Cancer. 2023 Feb;4(2):222-239. doi: 10.1038/s43018-022-00506-7. Epub 2023 Jan 23. Nat Cancer. 2023. PMID: 36690875 Free PMC article.
We report that dietary administration of L-fucose induces fucosylation and cell surface enrichment of the major histocompatibility complex (MHC)-II protein HLA-DRB1 in melanoma cells, triggering CD4(+) T cell-mediated increases in itICs and anti-tumor immunity, enhancing i …
We report that dietary administration of L-fucose induces fucosylation and cell surface enrichment of the major histocompatibility complex ( …
3,116 results